View : 53 Download: 0
Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial
- Title
- Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial
- Authors
- Jung, Ji-Jung; Cheun, Jong-Ho; Kim, Soo-Yeon; Koh, Jiwon; Ryu, Jai Min; Yoo, Tae-Kyung; Shin, Hee-Chul; Ahn, Sung Gwe; Park, Seho; Lim, Woosung; Nam, Sang-Eun; Park, Min Ho; Kim, Ku Sang; Kang, Taewoo; Lee, Jeeyeon; Youn, Hyun Jo; Kim, Yoo Seok; Yoon, Chang Ik; Kim, Hong-Kyu; Moon, Hyeong-Gon; Han, Wonshik; Cho, Nariya; Kim, Min Kyoon; Lee, Han-Byoel
- Ewha Authors
- 임우성
- SCOPUS Author ID
- 임우성
- Issue Date
- 2024
- Journal Title
- JOURNAL OF BREAST CANCER
- ISSN
- 1738-6756
2092-9900
- Citation
- JOURNAL OF BREAST CANCER vol. 27, no. 1, pp. 61 - 71
- Keywords
- Biopsy; Breast Neoplasms; Clinical Trial; Multicenter Study; Neoadjuvant Therapy
- Publisher
- KOREAN BREAST CANCER SOC
- Indexed
- SCIE; SCOPUS; KCI
- Document Type
- Article
- Abstract
- Purpose: Advances in chemotherapeutic and targeted agents have increased pathologic complete response (pCR) rates after neoadjuvant systemic therapy (NST). Vacuum-assisted biopsy (VAB) has been suggested to accurately evaluate pCR. This study aims to confirm the non-inferiority of the 5-year disease-free survival of patients who omitted breast surgery when predicted to have a pCR based on breast magnetic resonance imaging (MRI) and VAB after NST, compared with patients with a pCR who had undergone breast surgery in previous studies. Methods: The Omission of breast surgery for PredicTed pCR patients wIth MRI and vacuum- assisted bIopsy in breaST cancer after neoadjuvant systemic therapy (OPTIMIST) trial is a prospective, multicenter, single-arm, non-inferiority study enrolling in 17 tertiary care hospitals in the Republic of Korea. Eligible patients must have a clip marker placed in the tumor and meet the MRI criteria suggesting complete clinical response (post-NST MRI size <= 1 cm and lesion-to-background signal enhancement ratio <= 1.6) after NST. Patients will undergo VAB, and breast surgery will be omitted for those with no residual tumor. Axillary surgery can also be omitted if the patient was clinically node-negative before and after NST and met the stringent criteria of MRI size <= 0.5 cm. Survival and efficacy outcomes are evaluated over five years. Discussion: This study seeks to establish evidence for the safe omission of breast surgery in exceptional responders to NST while minimizing patient burden. The trial will address concerns about potential undertreatment due to false-negative results and recurrence as well as improved patient-reported quality of life issues from the omission of surgery. Successful completion of this trial may reshape clinical practice for certain breast cancer subtypes and lead to a safe and less invasive approach for selected patients.
- DOI
- 10.4048/jbc.2023.0265
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML